Dr. Stephen Chang to Present at CNS Diseases World Summit 2016

Boston, MA, July 06, 2016 --(PR.com)-- Dr. Stephen Chang, Vice President of Research and Development at the New York Stem Cell Foundation, will discuss rare and orphan CNS disorders at GTCbio’s CNS Diseases World Summit 2016 to be held on September 12th – 15th, 2016 at the Hyatt Boston Harbor in Boston, MA.

Dr. Stephen Chang has also been involved in the area of cell and gene therapy for the past 30 years in both academia and biotechnology. As the Vice President for Research and Development at NYSCF, Dr. Chang has overall responsibility for planning, coordinating, and managing the activities of the research department. In this role, he provides senior leadership in the areas of research and development, oversight of short and long term projects with regulations and policies related to administration and business units, partnerships with industry and other research institutions, and the monitoring and evaluation of projects. Prior to joining NYSCF, Dr. Chang served as Chief Scientific Officer of Stemgent upon the company's founding in 2008 and was previously the CEO of Multicell Technologies.

The CNS Diseases World Summit strives to go beyond just dialogue around research itself, but the partnerships and alliances that need to be formed in order to continue pushing research forward into the future. What are the best models of private/public partnerships? How are patient advocacy groups changing the way we think about funding and research? Colleagues will have the opportunity to build new relationships and move forward together towards the future of neuroscience. The CNS Diseases World Summit 2016 consists of two conferences:

10th Neurodegenerative Conditions Research & Development
I. Neuroinflammation Across CNS Disorders
II. Advances in Parkinson’s Disease Research & Therapeutics
III. Advances in Genetics and Systems Biology
IV. Biomarkers: Translation from Discovery to Clinical
V. Novel Therapeutics & Approaches in Alzheimer’s Disease
VI. Rare and Orphan CNS Disorders

9th CNS Partnering & Deal-Making
I. CNS: Present and Future
II. Partnering & Licensing in CNS
I. An Update on Neurodegeneration and the State of the Art
II. What Sells Big Pharma in CNS
III. Partnering with Patient Groups to Advance Research
IV. Regulatory Considerations for Orphan Drug Products
V. CNS Perspectives: Venture Capital and Public Markets

For more information, please visit the following website links:
www.gtcbio.com/conferences/cns-diseases-world-summit-overview

GTCbio
635 W. Foothill Blvd
Monrovia, CA 91016
www.gtcbio.com
Email: infogtcbio@gtcbio.com
Phone: (626) 256-6405
Fax: (626) 466-4433